IFNAR2 Protein & Antibody

Interferon (alpha, beta and omega) Receptor 2

IFNAR2 Products

IFNAR2 Protein, Recombinant

Molecule	Species	Description	Cat. No
IFNAR2	Human	IFNAR2/Fc Protein, Recombinant	10359-H02H
IFNAR2	Human	IFNAR2 Protein, Recombinant	10359-H08H

  10359-H02H: The EC₅₀ for this effect is typically 0.08-0.4 µg/mL. Measured by its ability to inhibit rh IFNβ mediated protection of WISH human amnion cells infected with vesicular stomatitis virus (VSV) to viral lysis.

  10359-H08H: The EC₅₀ for this effect is typically 0.08-0.4 µg/mL. Measured by its ability to inhibit rh IFNβ mediated protection of WISH human amnion cells infected with vesicular stomatitis virus (VSV) to viral lysis.

IFNAR2 Antibody

Molecule	Application	Description	Cat. No
Human IFNAR2	WB, ELISA	IFNAR2 Antibody, Rabbit PAb	10359-RP01
Human IFNAR2	WB, ELISA	IFNAR2 Antibody, Rabbit PAb (Antigen Affinity Purified)	10359-RP02
Human IFNAR2	WB, ELISA	IFNAR2 Antibody, Mouse MAb	10359-MM07

IFNAR2 cDNA Clone

Molecule	Species	Description	Cat. No
IFNAR2	Human	Homo sapiens IFNAR2 transcript variant 1 cDNA Clone	HG10359-M
IFNAR2	Cynomolgus	Cynomolgus monkey IFNAR2 cDNA Clone / ORF Clone	KG90112-G

IFNAR2 Related Areas

Cancer>>Angiogenesis>>Cytokines/Chemokines in Angiogenesis>>IFNAR2

Immunology>>Cytokine & Receptor>>Interleukin & Receptor>>IL-10/Interferon Family>>IFNAR2

IFNAR2 Alternative Names

IFNAR2, IFN-R, IFN-R-2, IFN-alpha-REC, IFNABR, IFNARB [Homo sapiens]

Ifnar2, AI747302, Ifnar-2 [Mus musculus]

IFNAR2 Background

Interferon-alpha/beta receptor beta chain (IFNAR2) is a type I membrane protein that forms one of the two chains of a receptor for interferons alpha and beta. Binding and activation of the receptor stimulates Janus protein kinases, which in turn phosphorylate several proteins, including STAT1 and STAT2. Initial cell-surface IFNAR2 expression at diagnosis assessed by flow cytometry widely distributed but showed overall significantly higher expression in CML patients when compared with normal controls. In 15 fresh patients who subsequently received IFNα therapy, IFNAR2 expression at diagnosis was significantly higher in cytogenetic good responders than in poor responders. Down-regulation of IFNAR2 expression during IFNα therapy was observed only in good responders but not in poor responders. The encoded protein also functions as an antiviral factor. IFNAR2 may associate with IFNAR1 to form the type I interferon receptor. This protein serves as a receptor for interferons alpha and beta. IFNAR2 is also involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity. Following binding of IFNα2, IFNAR2 is internalized, but, instead of being routed towards degradation as it is when complexed to IFNβ, it recycles back to the cell surface.

IFNAR2 Related Studies

1. Ito K, et al. (2004) Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia. Eur J Haematol. 73(3): 191-205.
2. Kim SH, et al. (1997) Mammalian type I interferon receptors consists of two subunits: IFNaR1 and IFNaR2. Gene. 196(1-2): 279-86.
3. Saleh AZ, et al. (2004) Regulated proteolysis of the IFNaR2 subunit of the interferon-alpha receptor. Oncogene. 23(42): 7076-86.